Literature DB >> 3987555

Electrophysiological effects of felodipine in combination with metoprolol.

C R Jones, A P Rae, M Been, P J de Vane, R R Jamieson, R S Hornung, W S Hillis.   

Abstract

The combined use of some beta-adrenoceptor blocking agents with calcium channel blockers may cause adverse pharmacodynamic drug interactions: hypotension, heart block or even asystole may be precipitated. The electrophysiological effects of combined administration of intravenous metoprolol 10mg and the vasodilating calcium antagonist felodipine (0.1 mg/kg/bodyweight) were assessed in an open study by invasive methods. Following metoprolol, the heart rate was reduced from 69 +/- 24 to 60 +/- 16 beats/min (mean +/- SD, p less than 0.05) with a minor prolongation of the sinus node recovery time. The A-H interval was increased from 94 +/- 25 to 109 +/- 16 msec (p less than 0.005) and the H-V interval was unchanged. The effective refractory period of the atrioventricular node was prolonged from 327 +/- 54 to 361 +/- 62 msec (p less than 0.01) with a minor prolongation of the effective refractory period of the ventricular Purkinje fibres. Systolic and diastolic blood pressures showed a mean reduction of 11 (p less than 0.001) and 6mm Hg (p less than 0.05), respectively. Following felodipine, the changes in heart rate and effective refractory periods of the atrioventricular node and ventricular Purkinje fibres returned towards control values. No further prolongation of the A-H interval resulted and further blood pressure changes were minor. The absence of adverse haemodynamic or electrophysiological effects suggests that this combination of agents may be safely used.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3987555     DOI: 10.2165/00003495-198500292-00015

Source DB:  PubMed          Journal:  Drugs        ISSN: 0012-6667            Impact factor:   9.546


  10 in total

1.  Electrophysiologic properties of intravenous oxprenolol in man.

Authors:  M Di Biase; R Guglielmi; A Scarcia; A Chiddo; P Rizzon
Journal:  J Electrocardiol       Date:  1977-07       Impact factor: 1.438

2.  Electrophysiological properties of intravenous metoprolol in man.

Authors:  P Rizzon; M Di Biase; A Chiddo; D Mastrangelo; L Sorgente
Journal:  Br Heart J       Date:  1978-06

3.  Electrophysiological effects of acebutolol.

Authors:  J W Mason; R A Winkle; P J Meffin; D C Harrison
Journal:  Br Heart J       Date:  1978-01

4.  The electrophysiology of propranolol in man.

Authors:  S F Seides; M E Josephson; W P Batsford; G M Weisfogel; S H Lau; A N Damato
Journal:  Am Heart J       Date:  1974-12       Impact factor: 4.749

5.  Electrophysiological effects of felodipine.

Authors:  M Been; P W Macfarlane; W S Hillis
Journal:  Drugs       Date:  1985       Impact factor: 9.546

6.  Antihypertensive effect of cardiovascular Ca2+-antagonist in hypertensive patients in the absence and presence of beta-adrenergic blockade.

Authors:  K Aoki; S Kondo; A Mochizuki; T Yoshida; S Kato; K Kato; K Takikawa
Journal:  Am Heart J       Date:  1978-08       Impact factor: 4.749

7.  Effect on mortality of metoprolol in acute myocardial infarction. A double-blind randomised trial.

Authors:  A Hjalmarson; D Elmfeldt; J Herlitz; S Holmberg; I Málek; G Nyberg; L Rydén; K Swedberg; A Vedin; F Waagstein; A Waldenström; J Waldenström; H Wedel; L Wilhelmsen; C Wilhelmsson
Journal:  Lancet       Date:  1981-10-17       Impact factor: 79.321

Review 8.  Comparative pharmacology of calcium antagonists: nifedipine, verapamil and diltiazem.

Authors:  P D Henry
Journal:  Am J Cardiol       Date:  1980-12-01       Impact factor: 2.778

9.  Clinical electrophysiological effects of atenolol--a new cardioselective beta-blocking agent.

Authors:  C Robinson; J Birkhead; B Crook; K Jennings; D Jewitt
Journal:  Br Heart J       Date:  1978-01

10.  Objective assessment of antianginal treatment: a double-blind comparison of propranolol, nifedipine, and their combination.

Authors:  P Lynch; H Dargie; S Krikler; D Krikler
Journal:  Br Med J       Date:  1980-07-19
  10 in total
  7 in total

Review 1.  Aspects on the benefit-risk balance of felodipine in hypertension.

Authors:  D Elmfeldt; S Westerling
Journal:  Drugs       Date:  1987       Impact factor: 9.546

Review 2.  Felodipine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in hypertension.

Authors:  E Saltiel; A G Ellrodt; J P Monk; M S Langley
Journal:  Drugs       Date:  1988-10       Impact factor: 9.546

3.  Felodipine in combination with a beta-adrenoceptor blocker as an effective substitute for triple therapy in severe hypertension. The Australian Felodipine Multicentre Study Group.

Authors:  D B Frewin; P Aldons; L L Wilson; E F O'Sullivan; R N Wyndham; J Karrasch; J Agar; B B Singh; B Jackson; P F Atkins
Journal:  Eur J Clin Pharmacol       Date:  1991       Impact factor: 2.953

Review 4.  'Second generation' dihydropyridine calcium antagonists. Greater vascular selectivity and some unique applications.

Authors:  D D Freedman; D D Waters
Journal:  Drugs       Date:  1987-11       Impact factor: 9.546

5.  Haemodynamic effects and pharmacokinetics of felodipine at rest and during exercise in hypertensive patients treated with metoprolol or atenolol.

Authors:  B Bengtsson-Hasselgren; D Elmfeldt; L Moberg; O Rönn
Journal:  Eur J Clin Pharmacol       Date:  1989       Impact factor: 2.953

Review 6.  Vascular selective calcium entry blockers in the treatment of cardiovascular disorders: focus on felodipine.

Authors:  W C Little; C P Cheng; L Elvelin; M Nordlander
Journal:  Cardiovasc Drugs Ther       Date:  1995-10       Impact factor: 3.727

7.  The efficacy and tolerability of long-term felodipine treatment in hypertension. The Scandinavian Multicenter Group.

Authors:  H Ibsen; B Westberg
Journal:  Cardiovasc Drugs Ther       Date:  1990-06       Impact factor: 3.727

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.